Gablicure 75 Capsule
Product Info
Prescription required | Yes |
Marketer | Curasia Medilabs |
Active Ingredient | Pregabalin (75mg) |
Storage | Store below 30°C |
Chemical Class | Cyclic GABA Analogues |
Habit Forming | No |
Therapeutic Class | NEURO CNS |
Action Class | Alpha 2 delta ligands (AED) |
User Rating | 4.2 |
User Reviews | 553 |
FAQ
Gablicure 75 Capsule Reviews
Gablicure 75 belongs to the anti-epileptic group of medicines and can also be used to treat certain types of seizures (fits) in combination with other medicines. Additionally, it may also be prescribed to treat the symptoms of anxiety disorder if other medicines are not suitable.
You can take Gablicure 75 with or without food, but it is important to take this medicine at the same time each day to get the most benefit. The exact dose and duration of treatment will depend on your condition and how you respond to it. Your doctor will probably start this medicine at a low dose and increase it gradually. It may take a few weeks for the medicine to work properly. Follow your doctor’s instructions and continue taking it regularly until your doctor advises you to stop. Do not miss any dose, otherwise, your condition may worsen.
The side effects of this medicine are usually mild and go away by themselves. The most common ones are feeling sleepy or dizzy, dryness in the mouth, blurred vision, weight gain, edema (swelling over the whole body), and difficulty in concentrating. Most side effects are not serious and do not need medical attention. Talk to your doctor about potential side effects and ways in which you might prevent or cope with them.
Before taking the medicine you should tell your doctor if you are pregnant, breastfeeding, or planning to become pregnant. Be careful while driving as sleepiness, dizziness, and blurring of vision may be seen as side effects. You should avoid drinking alcohol along with this medicine as it may lead to excessive sleepiness and dizziness.
How Gablicure 75 Capsule Works
How to Use Gablicure 75 Capsule
Benefits of Gablicure 75 Capsule
- In Treatment of Fibromyalgia: Gablicure 75 may also be used to treat pain in people with fibromyalgia. It reduces pain and also the mood changes, sleep problems, and tiredness that can be caused by the pain. It interferes with pain messages traveling through the brain. Keep taking the medicine until your doctor advises you to stop.
- In Treatment of Epilepsy/Seizures: Gablicure 75 belongs to a group of medicines called anticonvulsants which are used to treat some forms of epilepsy in adults. It is thought to work by slowing down nerve impulses in the brain which cause seizures (fits). It helps reduce symptoms such as confusion, uncontrollable jerking movements, loss of awareness, and fear or anxiety. It will help you go about your daily activities with more confidence and may allow you to do some activities that you would otherwise be forbidden or scared to do (such as swimming and driving). It can take a few weeks for this medicine to work and during this time you may still have seizures. Do not stop using this medicine even if you feel well until your doctor advises you to. Missing doses may trigger a seizure.
- In Treatment of Neuropathic pain: Gablicure 75 is used to treat long-lasting (chronic) pain caused by nerve damage due to diabetes, shingles, or spinal cord injury. It reduces pain and its associated symptoms such as mood changes, sleep problems, and tiredness. It is thought to work by interfering with pain signals that travel through the damaged nerves and the brain. Taking this medicine regularly will improve your physical and social functioning and overall quality of life. It takes a few weeks to work so you need to take it regularly even if you feel it is not doing any good. Once your symptoms have gone you should still keep taking the medicine until your doctor advises you to stop.
Uses of Gablicure 75 Capsule
- Treatment of Neuropathic pain
- Treatment of Fibromyalgia
- Treatment of Epilepsy/Seizures
Gablicure 75 Capsule Side Effects
Safety Tips
Quick Tips
- Do not stop taking the medication suddenly without talking to your doctor as it may worsen your underlying condition.
- It may cause blurring or loss of vision. Inform your doctor immediately if you notice any vision changes.
- It may cause sleepiness. Do not drive or do anything requiring concentration until you know how it affects you.
- Inform your doctor if you develop any unusual changes in mood or behavior, new or worsening depression, or suicidal thoughts or behavior.
- Gablicure 75 should be taken as per the dose and duration prescribed by your doctor.
References
- Porters RJ, Meldrum BS. Antiseizure Drugs. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 410.
- Pregabalin [Package Insert]. Solan, Himachal Pradesh: Torrent Pharmaceuticals Ltd.
- Pregabalin [Prescribing Information]. India: Alembic Pharmaceuticals Limited; 2023.
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Pregabalin. [Updated 2019 Oct 23].
- Pregabalin. Beverley, Hull: Dr. Reddy's Laboratories (UK) Ltd.; 2015 [revised 01 May 2018].
- Pregabalin. Sandwich, Kent: Pfizer Limited; 2009 [revised July 2018].
- Central Drugs Standard Control Organisation (CDSCO).
- Pregablin. New York, New York: Pfizer; 2004 [revised Jun. 2011].
- Lyrica (pregabalin): Frequently asked questions.
- Pregabalin. Vega Baja, Puerto Rico: Pfizer Pharmaceuticals LLC; 2009.
- Stahl SM, editor. Pregabalin. In: Stahl's Essential Pschopharmacology: Prescriber's Guide. 5th ed. New York, New York: Cambridge University Press; 2014. pp. 557-60.
- National Health Service. Pregabalin; 2018.
- McNamara JO. Pharmacotherapy of the Epilepsies. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 599.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 1149.